Security
Elite Pharmaceuticals, Inc. Common Stock · ELTP
ELTPOTCCommon stockCurrentCIK 1053369Updated Oct 20, 2026
Name history
ELITE PHARMACEUTICALS INC /DE/ · through Feb 8, 2012
ELTP price & chart
Loading TradingView…
OTC:ELTP on TradingView ↗About the company
Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops, manufactures, and distributes niche generic products. Elite’s product lines consist of immediate-release and controlled-release, solid oral dose products, which are marketed under the Elite Laboratories label, as well as pursuant to licenses granted to third-party pharmaceutical marketing and distribution organizations. Elite operates a cGMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ. For more information, visit www.elitepharma.com.
In the news
No coverage from other publishers is available.
Recent filings
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD Disclosure
Items 5.02, 7.01, 9.01
Results of Operations and Financial Condition · Regulation FD Disclosure
Items 2.02, 7.01, 9.01
10-Q filing
Regulation FD Disclosure
Items 7.01, 9.01
Regulation FD Disclosure
Items 7.01, 9.01
Show 5 more recent filings
Regulation FD Disclosure
Items 7.01, 9.01
Results of Operations and Financial Condition · Regulation FD Disclosure
Items 2.02, 7.01, 9.01
10-K filing
Regulation FD Disclosure
Items 7.01, 9.01
Regulation FD Disclosure
Items 7.01, 9.01
Financials
FY 2026 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2026 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2027 | Q1 2026 | Q1 2025 | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 126,412,637Source | 90,756,464Source | 74,696,279Source | 117,247,811Source | 88,197,996Source | 139,669,132Source | 111,339,370Source | 87,846,005Source | 138,289,840Source | 96,387,477Source | 83,653,536Source | 40,896,018Source |
| Property, Plant and Equipment, NetUSD | 10,035,389Source | 9,863,527Source | 10,095,029Source | 10,097,979Source | 10,176,587Source | 10,737,317Source | 10,270,036Source | 10,570,868Source | 10,181,328Source | 10,327,245Source | 10,175,293Source | 10,426,158Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | — | — | 5,816,211Source | — | — | — | — | — | — | — | 7,106,262Source | 7,832,247Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 48,529,574Source | 18,454,012Source | 16,009,614Source | 40,871,924Source | 21,443,555Source | 50,441,624Source | 36,218,671Source | 20,486,401Source | 59,715,676Source | 29,207,028Source | 19,453,301Source | 3,094,549Source |
| Inventory, NetUSD | 25,099,135Source | 20,157,890Source | 14,325,041Source | 18,164,934Source | 14,164,945Source | 24,200,388Source | 19,356,728Source | 13,831,318Source | 21,259,898Source | 16,240,376Source | 12,930,464Source | 9,550,716Source |
| Assets, CurrentUSD | 96,789,871Source | 48,049,677Source | 37,156,502Source | 85,793,698Source | 45,293,849Source | 114,487,702Source | 77,861,100Source | 43,160,540Source | 112,106,551Source | 57,739,147Source | 40,014,189Source | 21,510,297Source |
| Prepaid Expense and Other Assets, CurrentUSD | 2,066,258Source | 1,144,707Source | 1,005,636Source | 139,494Source | 130,386Source | 905,552Source | 547,904Source | 435,669Source | 1,333,177Source | 976,358Source | 524,162Source | 1,032,785Source |
| Operating Lease, Right-of-Use AssetUSD | 1,651,592Source | 2,110,917Source | 26,231Source | 1,770,693Source | 2,089,024Source | 1,404,216Source | 1,886,899Source | 2,222,172Source | 1,529,468Source | 2,000,284Source | 2,355,201Source | 13,062Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 46,098,554Source | 54,310,806Source | 28,282,558Source | 55,662,843Source | 40,930,976Source | 34,843,076Source | 63,656,727Source | 29,595,085Source | 39,406,865Source | 42,872,448Source | 26,070,718Source | 11,935,758Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | — | — | — | — | — | — | — | — | — | — | — | 13,903,960Source |
| Common Stock, Value, IssuedUSD | 1,074,600Source | 1,068,377Source | 1,017,885Source | 1,073,467Source | 1,068,377Source | 1,077,240Source | 1,068,467Source | 1,068,377Source | 1,077,200Source | 1,068,467Source | 1,068,377Source | 1,014,019Source |
| Additional Paid in CapitalUSD | 173,838,752Source | 173,385,785Source | 165,417,811Source | 173,704,576Source | 173,315,207Source | 173,976,332Source | 173,509,658Source | 173,262,878Source | 173,943,856Source | 173,457,329Source | 173,210,549Source | 164,750,980Source |
| Retained Earnings (Accumulated Deficit)USD | -94,292,428Source | -137,701,663Source | -119,715,134Source | -112,886,234Source | -126,809,723Source | -69,920,675Source | -126,588,641Source | -115,773,494Source | -75,831,240Source | -120,703,926Source | -116,389,267Source | -136,497,898Source |
| Stockholders' Equity Attributable to ParentUSD | 80,314,083Source | 36,445,658Source | 46,413,721Source | 61,584,968Source | 47,267,020Source | 104,826,056Source | 47,682,643Source | 58,250,920Source | 98,882,975Source | 53,515,029Source | 57,582,818Source | 28,960,260Source |
| Liabilities and EquityUSD | 126,412,637Source | 90,756,464Source | 74,696,279Source | 117,247,811Source | 88,197,996Source | 139,669,132Source | 111,339,370Source | 87,846,005Source | 138,289,840Source | 96,387,477Source | 83,653,536Source | 40,896,018Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 13,187,179Source | 14,688,832Source | 19,158,799Source | 10,673,516Source | 12,853,720Source | 30,441,614Source | 10,762,657Source | 14,014,635Source | 17,391,464Source | 11,840,435Source | 13,049,764Source | 7,833,637Source |
| Operating Lease, Liability, CurrentUSD | 519,739Source | 457,397Source | 26,231Source | 503,513Source | 422,323Source | 553,534Source | 487,759Source | 416,764Source | 536,427Source | 472,390Source | 411,418Source | 14,914Source |
| Accounts Payable, CurrentUSD | 6,522,108Source | 5,840,356Source | 2,890,717Source | 3,424,625Source | 1,983,280Source | 5,591,368Source | 5,088,869Source | 2,607,032Source | 6,053,444Source | 2,957,584Source | 2,714,306Source | 2,446,810Source |
| Operating Lease, Liability, NoncurrentUSD | 1,157,161Source | 1,676,900Source | — | 1,292,960Source | 1,741,240Source | 870,586Source | 1,424,120Source | 1,850,656Source | 1,015,647Source | 1,552,075Source | 1,957,383Source | — |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 5,547,783Source | 3,719,013Source | 11,884,645Source | 6,152,304Source | 5,703,464Source | 6,429,800Source | 4,581,743Source | 6,228,095Source | 10,194,222Source | 3,795,227Source | 5,301,747Source | 5,047,726Source |
| Deferred Revenue, CurrentUSD | — | — | 13,333Source | — | — | — | — | — | — | — | 13,333Source | 13,333Source |
| Deferred Revenue, NoncurrentUSD | — | — | 8,889Source | — | — | — | — | — | — | — | 5,556Source | 18,890Source |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | — | — | 22,161,000Source | — |
cash flow · annual statements
| Line item | Q4 2026 | Q4 2025 | Q3 2026 | Q3 2025 | Q2 2026 | Q2 2025 | Q1 2027 | Q1 2026 | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | 268,662Source | 313,060Source | 275,391Source | 227,356Source | 252,975Source | 275,413Source | 1,071,543Source | 1,226,399Source | 1,320,518Source | 1,277,622Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | -9,435,545Source | 7,223,068Source | 31,562,638Source | 9,904,985Source | 16,595,028Source | 36,636Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | 2,940,490Source | 3,116,352Source | 5,019,522Source | 3,309,912Source | 3,379,748Source | 2,809,546Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -462,076Source | 2,131,285Source | 3,095,860Source | 243,278Source | — | — |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | 1,321,731Source | 4,884,535Source | 10,542,709Source | 3,795,147Source | -19,989,000Source | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | 10,069,817Source | 14,775,842Source | 23,748,094Source | 7,455,639Source | -3,281,558Source | 3,338,704Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -808,964Source | -218,204Source | -925,626Source | -2,399,832Source | -809,653Source | -5,736,618Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 808,964Source | 218,204Source | 925,626Source | 1,625,082Source | 809,653Source | 5,736,618Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | -114,594Source | -4,130,684Source | -4,322,309Source | -825,740Source | 3,385,624Source | 1,702,199Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 9,146,259Source | 10,426,954Source | 18,500,159Source | 4,230,067Source | -705,587Source | -695,715Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 21,562,479Source | 8,742,284Source | 27,080,586Source | 9,999,087Source | 39,415,579Source | 22,196,115Source | 30,269,320Source | 11,769,161Source | 7,539,094Source | 8,244,681Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 27,170Source | 158,926Source | 246,118Source | 672,409Source | 119,412Source | 1,098,537Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | 19,547Source | — | 1,150,785Source | 612,085Source | 292,000Source | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 45,096Source | 70,578Source | 49,918Source | 52,329Source | 28,476Source | 52,329Source | 176,507Source | 227,565Source | 159,921Source | 39,325Source |
| Amortization of Debt Issuance CostsUSD | — | — | 80,204Source | 77,607Source | 82,470Source | 255,136Source | 73,103Source | 158,926Source | 396,664Source | — | — | — |
| DepreciationUSD | — | — | — | 313,060Source | — | 227,356Source | 252,975Source | 275,413Source | 1,071,543Source | 1,226,399Source | 1,320,518Source | 1,237,770Source |
| Derivative, Gain (Loss) on Derivative, NetUSD | — | — | 11,817,375Source | -11,729,368Source | 7,519,649Source | -12,754,735Source | 94,247Source | -22,109,537Source | 7,855,607Source | -18,901,185Source | -5,776,297Source | 415,126Source |
| Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber PropertyUSD | — | — | — | — | — | — | — | — | — | — | — | 1,000,000Source |
| Gain (Loss) on Sale of DerivativesUSD | — | — | — | — | — | — | 94,247Source | -22,109,537Source | 7,855,607Source | — | — | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | — | — | — | -1,603,426Source | — | -292,807Source |
| Gain (Loss) Related to Litigation SettlementUSD | — | — | — | — | — | — | — | — | — | — | 1,761,792Source | — |
| General and Administrative ExpenseUSD | — | — | 2,466,336Source | 2,724,616Source | 4,029,199Source | 2,273,744Source | 3,549,556Source | 3,404,084Source | 17,596,803Source | 9,001,930Source | 7,145,114Source | 5,122,272Source |
| Impairment of Intangible Assets (Excluding Goodwill)USD | — | — | — | — | — | — | — | — | 847,012Source | — | — | — |
| Income Tax Expense (Benefit)USD | — | — | 2,239,910Source | 239,175Source | 1,987,940Source | 1,517,203Source | 1,805,977Source | 5,320,501Source | 11,941,798Source | 4,262,519Source | -19,645,539Source | 424,028Source |
| Investment Income, InterestUSD | — | — | 83,602Source | 5,092Source | 4,922Source | 5,902Source | 166,117Source | 4,542Source | 207,857Source | 20,944Source | 20,918Source | 7,453Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | 18,593,806Source | -10,891,940Source | 13,702,407Source | -11,036,229Source | 5,910,565Source | -5,884,715Source | 44,872,686Source | -4,314,659Source | 20,108,631Source | 3,561,846Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | 18,593,806Source | -10,891,940Source | 13,702,407Source | -11,036,229Source | 5,910,565Source | -5,884,715Source | 44,872,686Source | -4,314,659Source | 20,108,631Source | 3,561,846Source |
| Nonoperating Income (Expense)USD | — | — | 11,820,773Source | -11,750,575Source | 7,476,601Source | -13,003,969Source | 187,261Source | -22,263,921Source | 7,701,300Source | -19,652,608Source | -10,325,677Source | 309,872Source |
| Operating ExpensesUSD | — | — | 3,940,232Source | 5,021,531Source | 5,859,287Source | 4,712,485Source | 5,978,264Source | 5,526,263Source | 25,911,151Source | 20,486,187Source | 15,568,334Source | 12,918,019Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 4,040Source | — | 318,753Source | 19,305Source | — | — |
| Stock or Unit Option Plan ExpenseUSD | — | — | — | — | — | — | 28,476Source | 52,329Source | 176,507Source | 227,565Source | 159,921Source | 39,325Source |
| Impairment of Intangible Assets, Finite-lived | — | — | — | — | — | — | — | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q4 2026 | Q4 2025 | Q3 2026 | Q3 2025 | Q2 2026 | Q2 2025 | Q1 2027 | Q1 2026 | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 31,589,251Source | 14,364,248Source | 36,321,704Source | 18,880,345Source | 32,355,283Source | 40,211,097Source | 148,870,119Source | 84,043,929Source | 56,625,128Source | 34,155,114Source |
| Cost of Goods and Services Sold | — | — | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source |
| Operating Income (Loss)USD | — | — | 9,012,943Source | 1,097,810Source | 8,213,746Source | 3,484,943Source | 7,529,281Source | 21,699,707Source | 49,113,184Source | 19,600,468Source | 10,788,769Source | 3,676,002Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | 20,833,716Source | -10,652,765Source | 15,690,347Source | -9,519,026Source | 7,716,542Source | -564,214Source | 56,814,484Source | -52,140Source | 463,092Source | 3,985,874Source |
| Income Tax Expense (Benefit)USD | — | — | 2,239,910Source | 239,175Source | 1,987,940Source | 1,517,203Source | 1,805,977Source | 5,320,501Source | 11,941,798Source | 4,262,519Source | -19,645,539Source | 424,028Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | 18,593,806Source | -10,891,940Source | 13,702,407Source | -11,036,229Source | 5,910,565Source | -5,884,715Source | 44,872,686Source | -4,314,659Source | 20,108,631Source | 3,561,846Source |
| Earnings Per Share, BasicUSD per share | — | — | 0.02Source | -0.01Source | 0.01Source | -0.01Source | 0.01Source | -0.01Source | 0.04Source | 0Source | 0.02Source | 0Source |
| Earnings Per Share, DilutedUSD per share | — | — | 0.01Source | -0.01Source | 0.01Source | -0.01Source | 0.01Source | -0.01Source | 0.03Source | 0Source | 0.02Source | 0Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 1,074,115,101Source | 1,068,273,108Source | 1,071,897,174Source | 1,068,273,108Source | 1,077,236,002Source | 1,068,363,108Source | 1,072,837,856Source | 1,068,290,368Source | 1,015,443,363Source | 1,012,911,346Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 1,140,876,178Source | 1,068,273,108Source | 1,141,536,381Source | 1,068,273,108Source | 1,128,661,497Source | 1,068,363,108Source | 1,138,368,235Source | 1,068,290,368Source | 1,023,225,623Source | 1,012,911,346Source |
| Additional Financial Items | ||||||||||||
| Current Income Tax Expense (Benefit)USD | — | — | — | -239,175Source | — | -1,517,203Source | — | — | 1,399,000Source | 468,000Source | 343,000Source | — |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | 388,135Source | 432,534Source | 394,864Source | 420,318Source | 367,761Source | 394,886Source | 1,547,874Source | 1,688,429Source | 1,379,948Source | 1,263,452Source |
| Gain (Loss) Related to Litigation SettlementUSD | — | — | — | — | — | — | — | — | — | — | 1,761,792Source | — |
| General and Administrative ExpenseUSD | — | — | 2,466,336Source | 2,724,616Source | 4,029,199Source | 2,273,744Source | 3,549,556Source | 3,404,084Source | 17,596,803Source | 9,001,930Source | 7,145,114Source | 5,122,272Source |
| Gross ProfitUSD | — | — | 12,953,175Source | 6,119,341Source | 14,073,033Source | 8,197,428Source | 13,507,545Source | 27,225,970Source | 75,024,335Source | 40,086,655Source | 26,357,103Source | 16,594,021Source |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 588,622Source | 1,112,707Source |
| Interest Expense, DebtUSD | — | — | 27,471Source | 31,089Source | 28,237Source | 33,135Source | 27,170Source | 28,797Source | 111,361Source | 128,234Source | 137,438Source | 1,013,874Source |
| Investment Income, InterestUSD | — | — | 83,602Source | 5,092Source | 4,922Source | 5,902Source | 166,117Source | 4,542Source | 207,857Source | 20,944Source | 20,918Source | 7,453Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | 18,593,806Source | -10,891,940Source | 13,702,407Source | -11,036,229Source | 5,910,565Source | -5,884,715Source | 44,872,686Source | -4,314,659Source | 20,108,631Source | 3,561,846Source |
| Nonoperating Income (Expense)USD | — | — | 11,820,773Source | -11,750,575Source | 7,476,601Source | -13,003,969Source | 187,261Source | -22,263,921Source | 7,701,300Source | -19,652,608Source | -10,325,677Source | 309,872Source |
| Operating ExpensesUSD | — | — | 3,940,232Source | 5,021,531Source | 5,859,287Source | 4,712,485Source | 5,978,264Source | 5,526,263Source | 25,911,151Source | 20,486,187Source | 15,568,334Source | 12,918,019Source |
| Research and Development ExpenseUSD | — | — | 1,040,665Source | 1,793,803Source | 1,385,306Source | 1,966,094Source | 2,032,471Source | 1,674,964Source | 5,742,955Source | 7,964,837Source | 6,883,351Source | 6,200,163Source |
Filing attachments
ex99-1.htm · 8-K · 2026-11-03
Exhibit 99.1 Elite Pharmaceuticals Expands Board of Directors with Election of Aqeel A. Fatmi, Ph. D., and John W. LaRocca, Esq. Northvale, NJ - November 3, 2026: Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCQB: ELTP), a specialty pharmaceutical company developing niche generic products, announced today that on October 28, 2026, its Board of Directors (the “Board”) increased the size of the Board from four to six directors and unanimously elected Aqeel A. Fatmi, Ph. D., and John …
Read attachment ↗ex99-1.htm · 8-K · 2026-08-13
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2027 ended June 30, 2026 and Provides Conference Call Information Conference Call Scheduled for Friday, August 14, 2026 at 11:30 AM EDT Northvale, NJ - August 13, 2026: Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCQB: ELTP), a specialty pharmaceutical company developing niche generic products, announced results for the first quarter of fiscal …
Read attachment ↗ex99-1.htm · 8-K/A · 2026-08-11
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss First Quarter of Fiscal Year 2027 Financial Results on August 14, 2026 Financials for First Quarter of Fiscal Year 2027 Ended June 30, 2026 will be released on Thursday, August 13, 2026 Northvale, NJ - August 10, 2026: Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCQB: ELTP), a specialty pharmaceutical company developing niche generic products…
Read attachment ↗ex99-1.htm · 8-K · 2026-08-10
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss First Quarter of Fiscal Year 2027 Financial Results on August 14, 2026 Financials for First Quarter of Fiscal Year 2027 Ended June 30, 2026 will be released on Thursday, August 13, 2026 Northvale, NJ - August 10, 2026: Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCQB: ELTP), a specialty pharmaceutical company developing niche generic products…
Read attachment ↗ex99-1.htm · 8-K · 2026-08-04
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Elite Pharmaceuticals Announces Commercial Launch of Generic Requip XL ® NORTHVALE, N.J. - August 4, 2026 - Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCQB: ELTP), a specialty pharmaceutical company developing niche generic products, today announced that the company has launched Elite’s generic version of Requip XL ® (Ropinirole Extended-Release Tablets USP), with strengths of 2 mg, 4 mg, 6 mg, 8 mg, and 12 mg tablets. Ropinirole belo…
Read attachment ↗ex99-1.htm · 8-K · 2026-06-29
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2026 and Provides Conference Call Information Conference Call Scheduled for Tuesday, June 30 at 11:30 AM EDT Northvale, NJ - June 29, 2026: Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCBB: ELTP), a specialty pharmaceutical company developing niche generic products, announced results for the fiscal year ended March 31, 2026 (“Fiscal 2026”). Con…
Read attachment ↗